Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Receivables for 15 consecutive years, with $31.3 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 27.41% to $31.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.3 million through Dec 2025, up 27.41% year-over-year, with the annual reading at $31.3 million for FY2025, 27.41% up from the prior year.
  • Receivables for Q4 2025 was $31.3 million at Gyre Therapeutics, up from $26.3 million in the prior quarter.
  • The five-year high for Receivables was $31.3 million in Q4 2025, with the low at $564000.0 in Q1 2022.
  • Average Receivables over 5 years is $13.4 million, with a median of $16.6 million recorded in 2023.
  • The sharpest move saw Receivables tumbled 45.13% in 2021, then soared 842.57% in 2022.
  • Over 5 years, Receivables stood at $1.8 million in 2021, then skyrocketed by 842.57% to $17.1 million in 2022, then dropped by 3.69% to $16.5 million in 2023, then surged by 48.75% to $24.5 million in 2024, then rose by 27.41% to $31.3 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $31.3 million, $26.3 million, and $25.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.